Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
about
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureWorking status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.Infliximab therapy modulates an antigen-specific immune response in chronic beryllium diseaseInfliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseasesAnti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative?Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionTumor necrosis factor as a therapeutic target of rheumatologic disease.Infliximab (Remicade) in the treatment of psoriatic arthritis.Health care utilization in patients with spondyloarthropathies.The efficacy and safety of golimumab in the treatment of arthritis.Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic.Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety.Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
P2860
Q26764867-8EB4F3DA-2E2A-4FD3-8200-199E74A8EDC5Q27012134-6E765A2A-5DFA-4001-95AA-B428A038646CQ33990812-05FFA401-CE73-41E5-AC0D-17AFC1441706Q34803148-C893846B-5065-4EB4-ABD4-84453EBCB6DDQ35141625-F59B18C7-9C7B-4002-B3C9-1842F3397A0EQ35760193-A9C214A7-F349-416E-AE2C-55F8EC314B2CQ35953468-3D3FA4D6-06F3-4CE3-A2B6-0D7985F7B8C1Q36033361-7CFFF837-9413-4ED0-B1F8-7027EC517C58Q36401927-9F725DDD-15F3-44AF-8DBC-BBD8EDD4D117Q36479450-05753124-86B0-41D1-BEE6-457A3256A64FQ36595046-F528F20A-5A6D-4C80-9938-E704BD1030BCQ36778450-734D332B-8176-494F-BC92-2C9EC950DF78Q37008829-27DE81AC-06F4-486C-8580-AC58AD8001DBQ37116853-F79479E6-9731-40C3-B8C9-6B774989A8A7Q37294500-AEC092A3-CB5E-460D-8445-7E5EAB7A6C15Q37760938-2C225CCE-D7C6-4B82-AAFF-18916C5BB20EQ37929647-E9CA4B3E-76B8-4238-8B88-E9FA3C608725Q38204241-60EA234B-723F-487F-A7CD-F6CBC6DFC521Q38268725-E95D5D64-561B-409E-87D3-66A322474EBCQ38630548-1DF7179E-6808-4557-A9CA-764EA0863D1BQ46467386-AED2C312-E563-460F-B5C3-F8D43E15FCA4Q47148249-B12CBD57-C845-4837-BCC8-959257D47CEEQ48559584-2C9A4EB7-EE37-408A-A374-8B356E1D854F
P2860
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Infliximab improves health rel ...... ents with psoriatic arthritis.
@ast
Infliximab improves health rel ...... ents with psoriatic arthritis.
@en
type
label
Infliximab improves health rel ...... ents with psoriatic arthritis.
@ast
Infliximab improves health rel ...... ents with psoriatic arthritis.
@en
prefLabel
Infliximab improves health rel ...... ents with psoriatic arthritis.
@ast
Infliximab improves health rel ...... ents with psoriatic arthritis.
@en
P2093
P2860
P356
P1476
Infliximab improves health rel ...... ents with psoriatic arthritis.
@en
P2093
A Kavanaugh
G G Krueger
L T Dooley
P2860
P304
P356
10.1136/ARD.2005.040196
P407
P577
2005-08-11T00:00:00Z